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From our physics classes, we can recall that developing a perpetual motion was a craze of the 19th 
century. Uncounted would-be inventors found themselves on the verge of discovering a machine that 
operated at 100% efficiency once started, or even greater efficiency, creating more energy than was used 
to run it. No matter the failures, these stalwarts soldiered on, convinced that they just had to refine and try 
one more time and they would have a critical breakthrough that would change the world. Eventually, the 
search fell to the wayside. We now look on perpetual motion as the product of incomplete understanding 
of the fundamentals of mechanics and entropy in a real-world system. Is history repeating itself in another 
field? 
In March of this year, all trials were terminated for aducanumab, another (out of at least half a dozen) 
“promising” antibody-based Alzheimer's disease (AD) therapy [1]. Aducanumab, a monoclonal antibody 
against amyloid-β (Aβ) peptide, had the key difference from some of its predecessors that it was specific 
against Aβ aggregates and did not recognize Aβ monomers. As is usual in these discontinued trials, it 
worked well in animal models and managed to get through safety trials. 
The ENGAGE and EMERGE trials for aducanumab were well designed, incorporating what was 
considered the best understanding of AD [1]. Subjects had to meet reasonable screening requirements: 
Clinical Dementia Rating of 0.5 (very mild), MMSE ≥ 24 (mild MCI or normal), positive PET for Aβ 
aggregates, and multiple exclusion criteria [1]. The antibody was administered monthly for 18 months. 
2 
 
Initial results looked promising, but futility analysis steered Eisai/Biogen to call everything to a halt. 
Leaving behind the ongoing controversy over the worth of futility analysis, this outcome was a 
disappointment to the field. 
So, what happened? Why did the latest best great hope fizzle? Was it a good fizzle or a bad fizzle? Did 
we learn anything from the failure? That remains to be seen, depending on how forthcoming the study’s 
owners are with their data. Nevertheless, this latest failure, regardless of what gets published, can be 
capitalized on, simply because it is a failure. 
From sports jargon, some coaches refer to what they call “harder-faster syndrome”. This refers to a 
common response to failure of redoubling efforts in the same direction, merely harder and faster. A more 
viable tactic is to treat failure as an opportunity to explore alternative approaches. Current approaches 
share two critical traits: The treatments, regardless of their individual targets, each have a single target. 
They presume that AD stands on a single protein, and all you have to do is knock over that support to 
bring the entire disease down (“stilt” approach). Within these approaches, the majority are aggregate-
based. Either knock out tau or knock out Aβ, but if you remove an aggregate, everything should just fall 
into place (“clump-cleanup”). Unfortunately, both approaches are based on what the field is beginning to 
admit may be an incomplete model of AD. 
AD is unlikely to be a single-molecule disorder. Unfortunately, most understanding of AD is based on 
familial AD (FAD), which is atypical of AD. Known risk (and, by extension, protective) factors vs. the 
most common form, sporadic AD, do not apply to FAD. Thus, treatments heavily derived from studying 
animal models based on FAD may be foredoomed. AD is an amyloidopathy and a tauopathy and a gliosis 
and a metallo-dyshomeostasis, among other features, and the primacy of any of these disease traits over 
any others has not been established. 
Likewise, any of the failed treatments cannot be said to have addressed causes of AD, not due to their 
failures but because the causes of AD are still unknown. If advanced aggregation of Aβ plaque and tau 
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tangle actually determine AD, why are there people of advanced age who have plaques and tangles but no 
dementia? The most common response in the field sounds unconvincing: These people still have AD but 
they do not have dementia. From the perspective of patients and families, dementia is the only thing that 
matters and they would not care if plaques and tangles multiplied so long as normal living were restored. 
In a very fundamental way, we still do not know how AD starts or even what it is. 
Nevertheless, this does not mean we should surrender. We can still say that in many cases, aggregates are 
likely to have something to do with progression of AD as a life-altering disease. However, as has been 
stated more times than can be counted, attacking the aggregate stage may be “too late”. Of course, if 
dealing with the aggregates once they have appeared is “too late”, does that mean that the aggregates are 
just a symptom of AD? In any case, once the molecular hallmarks appear, cellular damage may be 
irreversible. In addition, how early is early enough? Everyone in an industrial country has been exposed 
to some risk factor or another for sporadic AD, be it pollution, stress, heavy metals, a poor diet, social 
alienation, or multiple other selections. Does the “ever earlier” mantra mean that we simply must put 
everyone over the age of 30 on anti-AD drugs for the rest of their lives? What approaches could work? 
AD is complex and heterogeneous. AD can be slow developing and chronic. AD researchers can learn 
something from metabolic disorders, cardiovascular disorders, and cancers. These three disease fields 
embrace cocktail and multi-therapy approaches. Why not AD treatment? AD has proved time and again 
immune to any single-target approach. Rather than focus on traits of advanced diabetes or heart failure, or 
on stage 4 cancer, research focuses on finding ever-earlier, accurate detection and identification of 
meaningful precursors. 
Likewise tackling AD requires multiple steps. Primary preventive steps, such as lifestyle, and 
supplemental interventions, needs to preceed any disease-modifying interventions, such as anti-amyloid 
or tau therapy, vaccination, or pioglitazone [2]. Such measures should be considered secondary 
interventions, not primary, much as lifestyle modification is primary to preventing metabolic and 
cardiovascular disorders, and drugs are a second line of defense. This also requires our understanding the 
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disease as a transformation rather than a state [3]. This opens up exploring other less-studied areas 
relevant to AD, such as clinical and environmental correlates, and epigenetic factors [2 - 4] 
Treatments could combine symptomatic (such as, cholinergic modulators, anti-cholinesterase, anti-
NMDA receptor) along with anti-amyloid and anti-tau drugs. As knowledge improves, the cocktails could 
be improved. Current one-target-only approaches mean that a substance that might improve upon current 
treatments if used in conjunction are rejected because they do not solve the entire problem on their own. 
In addition, how often is lifestyle change advised by physicians for early metabolic or cardiovascular 
signs or symptoms? Quite often! Are physicians taught to do the same regarding AD? Where does 
prevention currently fit in the family physician’s arsenal against averting AD, or is AD simply kicked 
down the road and never discussed until serious symptoms appear. 
The amazing success of antibiotics in the 20th century may have instilled an unfortunate “heroic 
pharmaceuticals” paradigm, where a magic bullet shoots the magic target and magically eradicates the 
disease. In general, bacterial infections are far simpler affairs than a sporadic neurodegenerative disease. 
The ongoing (desperate?) search by a few researchers for an infectious agent behind AD may reflect a 
desire to have such a simple paradigm. After all, a previously sporadic disorder, gastric ulcers, was found 
to actually be predominantly due to a single infectious agent. However, such a possibility is remote for 
AD. The possibility of applying the antibiotic paradigm of one target, one drug, one cure is equally as 
remote. 
Tackling a disorder with the complexity of AD will require us to meet it with an arsenal, not a magic 
bullet. We need to continue mechanistic studies [5], test potential drug targets, and include lifestyle 
changes in our clinical responses. In addition, we will need to go beyond obvious symptoms and discover 
valid precursors that appear early enough to be reversed. The field must consider AD-Ditional preventive 
approaches instead of "A Drug" to avert AD. 
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